UNITY Biotechnology, Inc. is a biotechnology company engaged in researching and developing therapeutics to slow, halt or reverse diseases of aging. The Company is focused on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. It is targeting specific biological mechanisms implicated in diseases of aging. Its core therapeutic approach targets cellular senescence, and it is advancing senolytic programs primarily in ophthalmologic disorders. It has other programs based on other biologies of aging to include an agonistic antibody to the Tie2 receptor and a Tie2/VEGF bispecific to treat vascular eye disease. UBX1325 is its advanced drug candidate for age-related diseases of the eye, including diabetic macular edema. UBX1325 is a potent small molecule inhibitor of BCL-xL. UBX2089, an a-Klotho hormone drug candidate, is being researched for multiple neurology indications.

• Revenue in USD (TTM)0.00
• Net income in USD-27.50m
• Incorporated2009
• Employees16.00

• Location
  UNITY Biotechnology Inc285 EAST GRAND AVENUESOUTH SAN FRANCISCO 94080United StatesUSA
• Phone+1 (650) 416-1192
• Fax+1 (302) 655-5049
• Websitehttps://unitybiotechnology.com/